Updated on 2022/03/31


Nagoya University Hospital Radiology Assistant professor of hospital
Assistant professor of hospital

Degree 1

  1. Doctor of Philosophy (Medical Science) ( 2021.3   Nagoya University ) 

Research Areas 1

  1. Life Science / Tumor diagnostics and therapeutics

Current Research Project and SDGs 2

  1. 頭蓋内悪性腫瘍の放射線治療

  2. 他施設での放射線治療データ共有の円滑化

Research History 1

  1. Nagoya University   Assistant professor of hospital

Education 1

  1. Nagoya University

Professional Memberships 2

  1. 日本医学放射線学会

  2. 日本放射線腫瘍学会

Committee Memberships 5

  1.   強度変調放射s年治療システム試用策定委員  


  2.   薬事委員  


  3.   マスタ委員  


  4.   カルテ監査委員  


  5.   移動型投資用エックス線装置仕様策定委員  



Papers 14

  1. Poor local control of ulcerative T1 glottic cancer treated with 2.25-Gy per fraction radiotherapy

    Oie Yumi, Itoh Yoshiyuki, Kawamura Mariko, Takase Yuuki, Murao Takayuki, Ishihara Shunichi, Nomoto Yoshihito, Hirasawa Naoki, Asano Akiko, Yamakawa Kouji, Ito Junji, Kinoshita Fumie, Naganawa Shinji

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 83 ( 4 ) page: 811 - 825   2021.11

     More details

    Language:Japanese   Publisher:Nagoya Journal of Medical Science  

    The Tokai Study Group for Therapeutic Radiology and Oncology (TOSTRO) started managing T1 glottic cancer using 2.25 Gy/fraction radiotherapy in 2011. The aim was to evaluate the local control (LC) rate and toxicity with 2.25-Gy radiotherapy in clinical practice and identify prognostic factors.The eligibility criteria were T1 glottic squamous cell carcinoma patients with age ≥20 years, treated with 2.25 Gy/fraction without chemotherapy between 2011 and 2017. LC rates were evaluated based on age, performance status, sex, T-category, tumor type (ulcerative or non-ulcerative), presence of anterior commissure invasion, tumor size, X-ray beam energy, and overall treatment time. Acute and late adverse events were evaluated using CTCAE version 4.0. A total of 202 patients were enrolled. The median follow-up period was 34.2 months. The 2 and 4-year LC rates were 93.8% and 93.1%, respectively. There was a significant difference in the LC rate between non-ulcerative type and ulcerative type (95.2% vs. 74.1% at 2 years, 94.4% vs. 74.1% at 4 years; p = 0.01). On univariate analysis, only tumor type was significantly correlated with a poor LC rate (hazard ratio 4.3; 95% confidence interval 1.2–15.4; p = 0.03). Acute grade 3 adverse events occurred in 17 patients. However, no late adverse events of grade 3 or higher have occurred to date. T1 glottic cancer treatment outcomes using hypofractionated radiotherapy with 2.25 Gy/fraction in clinical practice were comparable to previously reported results. However, ulcerative type tumor was associated with a poor LC rate.

    DOI: 10.18999/nagjms.83.4.811

    Web of Science


  2. The importance of choosing the right strategy to treat small cell carcinoma of the cervix: a comparative analysis of treatments

    Kawamura Mariko, Koide Yutaro, Murai Taro, Ishihara Shunichi, Takase Yuuki, Murao Takayuki, Okazaki Dai, Yamaguchi Takahiro, Uchiyama Kaoru, Itoh Yoshiyuki, Kodaira Takeshi, Shibamoto Yuta, Mizuno Mika, Kikkawa Fumitaka, Naganawa Shinji

    BMC CANCER   Vol. 21 ( 1 )   2021.9

     More details

    Language:Japanese   Publisher:BMC Cancer  

    Background: Standard treatments for small cell carcinoma of the cervix (SCCC) have not been established. In this study, we aimed to estimate the optimal treatment strategy for SCCC. Methods: This was a multicenter retrospective study. Medical records of patients with pathologically proven SCCC treated between 2003 and 2016 were retrospectively analyzed. Overall survival (OS) was plotted using the Kaplan-Meier method. Log-rank tests and Cox regression analysis were used to assess the differences in survival according to stage, treatment strategy, and chemotherapy regimen. Results: Data of 78 patients were collected, and after excluding patients without immunohistopathological staining, 65 patients were evaluated. The median age of the included patients was 47 (range: 24–83) years. The numbers of patients with International Federation of Gynecology and Obstetrics (FIGO) 2018 stages I-IIA, IIB-IVA, IVB were 23 (35%), 34 (52%), and 8 (12%), respectively. Of 53 patients who had undergone chemotherapy, 35 and 18 received SCCC and non-SCCC regimens as their first-line chemotherapy regimen, respectively. The 5-year OS for all patients was 49%, while for patients with FIGO stages I-IIA, IIB-IVA, IVB, it was 60, 50, and 0%, respectively. The 5-year OS rates for patients who underwent treatment with SCCC versus non-SCCC regimens were 59 and 13% (p < 0.01), respectively. This trend was pronounced in locally advanced stages. Multivariate analysis showed that FIGO IVB at initial diagnosis was a significant prognostic factor in all patients. Among the 53 patients who received chemotherapy, the SCCC regimen was associated with significantly better 5-year OS in both the uni- and multivariate analyses. Conclusion: Our results suggest that the application of an SCCC regimen such as EP or IP as first-line chemotherapy for patients with locally advanced SCCC may play a key role in OS. These findings need to be validated in future nationwide, prospective clinical studies.

    DOI: 10.1186/s12885-021-08772-x

    Web of Science


  3. Stereotactic body radiation therapy for Japanese patients with localized prostate cancer: 2-year results and predictive factors for acute genitourinary toxicities

    Ito Makoto, Yoshioka Yasuo, Takase Yuuki, Suzuki Junji, Matsunaga Takuma, Takahashi Hironori, Takeuchi Arisa, Adachi Sou, Abe Souichirou, Oshima Yukihiko, Ohtakara Kazuhiro, Suzuki Kojiro, Okuda Takahito

    JAPANESE JOURNAL OF CLINICAL ONCOLOGY   Vol. 51 ( 8 ) page: 1253 - 1260   2021.8

     More details

    Language:Japanese   Publisher:Japanese Journal of Clinical Oncology  

    Objective: We aimed to report the 2-year results of stereotactic body radiation therapy for prostate cancer and identify the clinical and dosimetric factors that predict acute genitourinary toxicities. Methods: We retrospectively reviewed the medical records of patients with non-metastatic prostate cancer treated at Toyota Memorial Hospital between 2017 and 2020. The patients were treated with stereotactic body radiation therapy with a total dose of 36.25 Gy in five fractions on consecutive weekdays. While low-risk patients received radiotherapy alone, intermediate- to high-risk patients also received androgen deprivation therapy. Results: We analysed a total of 104 patients, including 10, 60 and 34 low-, intermediate- and high-risk patients, respectively. The median follow-up duration was 2 years. We did not observe biochemical/clinical recurrence, distant metastasis or death from prostate cancer. One patient died of another cause. Grade 2 acute genitourinary toxicity was observed in 40 (38%) patients. Age (P = 0.021), genitourinary toxicity of grade ≥1 at baseline (P = 0.023) and bladder mean dose (P = 0.047) were significantly associated with the incidence of grade 2 acute genitourinary toxicity. The cut-off value of 65 years for age and 10.3 Gy for the bladder mean dose were considered the most appropriate. Grade 2 acute gastrointestinal toxicity was observed in five (5%) patients. None of the patients experienced grade ≥3 acute or late toxicity. Conclusions: Stereotactic body radiation therapy is feasible for Japanese patients with prostate cancer, with acceptable acute toxicity. Age, genitourinary toxicity at baseline and bladder mean dose predict grade 2 acute genitourinary toxicity.

    DOI: 10.1093/jjco/hyab094

    Web of Science


  4. Can we safely lower the RT dose with the use of high dose PF for advanced cervical cancer?

    Kawamura M., Nakahara R., Ishihara S., Oie Y., Takase Y., Okumura M., Ito J., Ono T., Itoh Y., Naganawa S.

    RADIOTHERAPY AND ONCOLOGY   Vol. 161   page: S1064 - S1065   2021.8

     More details


    Web of Science

  5. SBRT for Japanese patients with prostate cancer: prediction of acute genitourinary toxicities

    Ito M., Takase Y., Suzuki J., Matsunaga T., Takahashi H., Takeuchi A., Adachi S., Abe S., Oshima Y., Ohtakara K., Yoshioka Y., Suzuki K., Okuda T.

    RADIOTHERAPY AND ONCOLOGY   Vol. 161   page: S1101 - S1101   2021.8

     More details


    Web of Science

  6. Dosimetric impacts of beam-hardening filter removal for the CyberKnife system.

    Kamomae T, Matsunaga T, Suzuki J, Okudaira K, Kawabata F, Kato Y, Oguchi H, Shimizu M, Sasaki M, Takase Y, Kawamura M, Ohtakara K, Itoh Y, Naganawa S

    Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)   Vol. 86   page: 98 - 105   2021.5

     More details

    Language:English   Publisher:Physica Medica  

    DOI: 10.1016/j.ejmp.2021.05.011



  7. Early glottic cancer treatment with concurrent chemoradiotherapy with once-daily orally administered S-1

    Takase Yuuki, Itoh Yoshiyuki, Ohtakara Kazuhiro, Kawamura Mariko, Ito Junji, Oie Yumi, Ono Tamami, Sasaki Yutaro, Nishida Ayumi, Naganawa Shinji

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 83 ( 2 ) page: 251 - 258   2021.5

     More details


    DOI: 10.18999/nagjms.83.2.251

    Web of Science

  8. Comparison of Physician-recorded Toxicities and Patient-reported Outcomes of Five Different Radiotherapy Methods for Prostate Cancer

    Ito Makoto, Sasamura Kazuma, Takase Yuuki, Kotsuma Tadayuki, Oshima Yukihiko, Minami Yoshitaka, Suzuki Junji, Tanaka Eiichi, Ohashi Wataru, Oguchi Masahiko, Okuda Takahito, Suzuki Kojiro, Yoshioka Yasuo

    ANTICANCER RESEARCH   Vol. 41 ( 5 ) page: 2523 - 2531   2021.5

     More details

    Language:Japanese   Publisher:Anticancer Research  

    DOI: 10.21873/anticanres.15030

    Web of Science


  9. A case of neuroblastoma relapsing early after high-dose chemotherapy and causing pleural dissemination Reviewed

    Maemura Ryo, Yamashita Daiki, Sajiki Daichi, Sakaguchi Hirotoshi, Yoshida Nao, Chiba Kousuke, Murase Naruhiko, Takase Yuki, Yamada Tetsuya, Yoshikawa Kanae, Ito Ai, Ito Masafumi, Iwamoto Shotaro, Hama Asahito

    The Japanese Journal of Pediatric Hematology / Oncology   Vol. 58 ( 2 ) page: 171 - 174   2021

     More details

    Language:Japanese   Publisher:The Japanese Society of Pediatric Hematology / Oncology  

    <p>Here, we describe the case of a 14-month-old boy with a left retroperitoneal tumor that was diagnosed as stage 3 neuroblastoma (image-defined risk-factor-positive, <i>MYCN</i> amplified). He underwent five courses of induction chemotherapy and high-dose chemotherapy comprising busulfan+melphalan, followed by autologous bone marrow transplantation. On day 72 after transplantation, he underwent partial resection, and a histopathological analysis showed surviving viable tumor cells. On day 77, computed tomography (CT) scan showed progression of the primary tumor. Although salvage therapy was performed, CT scan on day 100 showed multiple pleural metastases. Local irradiation of the primary tumor (30.6 Gy/17 fractions) and whole lungs (15 Gy/10 fractions) was also performed. Peritoneal dissemination occurred and he died on day 207. Post-autopsy analysis showed high expression levels of ALK in the primary tumor and autopsy specimens. Neuroblastoma with <i>MYCN</i> amplification and high expression levels of ALK can result in rapid exacerbation, and the introduction of new agents such as ALK inhibitors is warranted.</p>

    DOI: 10.11412/jspho.58.171

    CiNii Research

  10. Comparison of Physician-Recorded Toxicities and Patient-Reported Outcomes Among 5 Different Radiotherapy Methods for Prostate Cancer

    Ito M., Takase Y., Sasamura K., Kotsuma T., Ooshima Y., Minami Y., Suzuki J., Tanaka E., Oguchi M., Okuda T., Suzuki K., Yoshioka Y.


     More details


    Web of Science

  11. Clinical Results of T1 Glottic Cancer Treated with Radiotherapy Using 2.25 Gy per Fractions: A Multicenter Survey in Clinical Practice

    Oie Y., Itoh Y., Kawamura M., Takase Y., Murao T., Ishihara S., Nomoto Y., Hirasawa N., Asano A., Yamakawa K., Ito J., Naganawa S.


     More details


    Web of Science

  12. Should Small Cell Carcinoma of the Cervix be Treated As Localized Small Cell Cancer or Advanced Cervical Cancer: A Retrospective Multi-Institutional Cohort Study

    Kawamura M., Koide Y., Murai T., Ishihara S., Takase Y., Murao T., Okazaki D., Yamaguchi T., Uchiyama K., Itoh Y., Kodaira T., Shibamoto Y., Mizuno M., Kikkawa F., Naganawa S.


     More details


    Web of Science

  13. Study protocol: Prospective study of concurrent chemoradiotherapy with S-1 and hypofractionated radiotherapy for outpatients with early glottic squamous cell carcinomas

    Kimura K.

    Asian Pacific Journal of Cancer Prevention   Vol. 19 ( 5 ) page: 1195 - 1199   2018.5

     More details

    Publisher:Asian Pacific Journal of Cancer Prevention  

    DOI: 10.22034/APJCP.2018.19.5.1195


  14. Optimized treatment strategy of radiotherapy for early glottic squamous cell carcinomas: An initial analysis

    Kimura Kana, Itoh Yoshiyuki, Okada Tohru, Kubota Seiji, Kawamura Mariko, Nakahara Rie, Oie Yumi, Kozai Yuka, Takase Yuuki, Tsuzuki Hidenori, Nishio Naoki, Hiramatsu Mariko, Fujimoto Yasushi, Mizutani Takefumi, Naganawa Shinji

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 79 ( 3 ) page: 331 - 338   2017.8

     More details

    Publisher:Nagoya Journal of Medical Science  

    DOI: 10.18999/nagjms.79.3.331

    Web of Science


▼display all

Books 1

  1. 肺癌の体幹部定位放射線治療

    高瀬裕樹、佐貫直子、石原俊一( Role: Joint author ,  筆頭著者)

    科学論評者  2022.2 

     More details

    Total pages:6   Responsible for pages:6   Language:Japanese Book type:Scholarly book

Presentations 1

  1. Malignant International conference

    Takase Y., Kawamura M., Nakahara R., Itoh J., Oie Y., Okumura M., Kamomae T., Itoh Y., Ono T., Naganawa S.


     More details

    Language:English   Presentation type:Poster presentation  

KAKENHI (Grants-in-Aid for Scientific Research) 1

  1. 悪性神経膠腫放射線治療における高精度/高再現性標的体積決定法の開発

    Grant number:20K16756  2020.4 - 2024.3


    高瀬 裕樹

      More details

    Authorship:Principal investigator 

    Grant amount:\3770000 ( Direct Cost: \2900000 、 Indirect Cost:\870000 )



Teaching Experience (On-campus) 1

  1. 放射線腫瘍学特論